Quarterly report pursuant to Section 13 or 15(d)

LIQUIDITY (Details)

v3.22.4
LIQUIDITY (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jan. 31, 2022
Dec. 31, 2020
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
Jun. 30, 2022
Net loss     $ (13,556) $ (12,593) $ (23,387) $ (20,429) $ (41,100)
Net cash used in operating activities         (15,082) $ (13,538) (39,600)
Accumulated deficit     (232,585)   (232,585)   (209,198)
Cash and cash equivalents     146,746   146,746   150,410
Current liabilities     $ 6,313   6,313   $ 2,462
XOMA (US) LLC [Member] | Phase 2 Clinical Trial RZ358 | Xoma License Agreement [Member]              
Milestone closing payment $ 2,000            
XOMA (US) LLC [Member] | Phase 3 Clinical Trial Rz 358 | Xoma License Agreement [Member] | Plan              
Milestone closing payment $ 5,000       5,000    
ActiveSite Pharmaceuticals, Inc | Development And License Agreement [Member]              
Milestone closing payment   $ 1,000          
ActiveSite Pharmaceuticals, Inc | Phase 2 Clinical Trial RZ402 | Development And License Agreement [Member] | Plan              
Milestone closing payment         $ 3,000